Semprus BioSciences Inc

Parents

*Architects: Biotechnology_Immunotherapy & Inflammation
*Industry: Massachusetts
Contractors/Awardees: TATRC
NIH: R&D Awardees
SBIR (Small Business Innovation Research) Program-NSF Awardees

Children

5AM Ventures and Pangaea Ventures, both of whom invested in the company’s Series A financing, participated in the Series B roun
A profound revolution in the cost of DNA sequencing has enabled the company to develop brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes.
Cambridge, Massachusetts
Closed on an $18 million Series B financing round, led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (2010)
Dr Robert Langer, Phd, Germeshausen Professor of Chemical & Biomedical Engineering, David H. Koch Institute, MIT (2026)
Founded 2008
Partnership between the founding team at Mohr Davidow Ventures who seeded the venture to explore ways of expanding the use of next generation DNA sequencing platforms in molecular diagnostics.
Semprus socks away $18M in Series B funds
SEMPRUS_BIOSCIENCES_AWARDED_$1_MILLION_U S _ARMY_GRANT_TO_DEVELOP_ANTI-BIOFILM_TRAUMA_DEVICES_FOR_AMERICAN_SOLDIERS_IN_BATTL
Sequenta (Formerly MLC Dx, Inc.) is a venture funded biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status.
The company was founded in 2008 by entrepreneurs who previously founded ParaAllele BioScience, a successful startup company sold to Affymetrix in 2005.
Total of non-equity R&D funding Semprus has secured to $2.5 million, from the U.S. Department of Defense, the U.S. Department of Energy, the National Institutes of Health and the National Science Foundation.

Jumps

GlaxoSmithKline plc (GSK)
MIT (Massachusetts Institute of Technology)

Made with TheBrain